Business
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadershipVancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership","length":162,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company expands its portfolio of next-generation thermal-stability technologies for temperature-sensitive medications.","length":615,"tagName":"p"},{"type":"text","content":"Prof. Heinemann is internationally recognized for pioneering work that bridges insulin pharmacology, diabetes technology, and drug-stability science. As co-founder of the Profil Institute for Metabolic Research and former Managing Editor of the Journal of Diabetes Science and Technology, he has played a central role in advancing insulin kinetics, continuous glucose monitoring (CGM), artificial pancreas systems, and the clinical translation of new diabetes technologies.","length":473,"tagName":"p"},{"type":"text","content":"Beyond device innovation, Prof. Heinemann has published foundational research demonstrating the critical impact of temperature on insulin and other peptide-based medications, highlighting how improper storage outside the cold chain can degrade potency, reduce therapeutic effectiveness, and compromise patient safety. His dual expertise-deep scientific understanding paired with real-world medication-handling insights-positions him as a global authority on the clinical implications of thermal instability.","length":507,"tagName":"p"},{"type":"text","content":""As a researcher who has spent decades investigating how temperature fluctuations impact the stability and safety of insulin and other injectable medications, I have seen firsthand how real-world storage conditions can jeopardize treatment outcomes. TempraMed's technologies offer a scientifically sound and practical solution to ...